Irenor (Reboxetine)

Reboxetine is a selective norepinephrine reuptake inhibitor used in the treatment of depressive disorders.

• Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients.

• Reboxetine blocks the norepinephrine transporter (NET) on presynaptic neurons, preventing the reuptake of norepinephrine from the synaptic cleft. This inhibition raises extracellular norepinephrine concentrations, enhancing noradrenergic neurotransmission, which contributes to mood elevation and reduction of depressive symptoms.

Reboxetine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset that often resolves with continued use.
• Dry mouth: reduced salivation leading to a feeling of thirst.
• Insomnia: difficulty falling or staying asleep.
• Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects

• Elevated blood pressure: significant rise requiring medical monitoring.
• Suicidal thoughts or behavior: emergence or worsening of depressive ideation.
• Severe liver injury: rare hepatotoxicity presenting with jaundice or abnormal liver tests.

Before initiating therapy, clinicians should consider several safety measures.

• Assess cardiovascular status: monitor blood pressure and heart rate regularly.
• Review psychiatric history: watch for worsening depression or emergence of suicidal ideation.
• Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal effects.
• Use caution in hepatic impairment: evaluate liver function and adjust therapy if necessary.
• Pregnancy and lactation: discuss potential risks with the prescriber before use.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Reboxetine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis.
• Tricyclic antidepressants: combined therapy can increase cardiovascular side effects.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may mask tachycardia, requiring heart‑rate monitoring.

• Antihypertensive agents: additive blood‑pressure‑lowering effect may occur.
• CYP2D6 inhibitors (e.g., fluoxetine, quinidine): can raise reboxetine plasma concentrations, necessitating dose adjustment.